Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Wilms Tumor 1Testicular Neoplasms 1Teratoma 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Liver Neoplasms 1Kidney Neoplasms 1Familial ependymoma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Astrocytoma 1

Interventions

Sunitinib 145Nivolumab 144pembrolizumab 132Sorafenib 84Bevacizumab 77Everolimus 74cabozantinib 71pazopanib 65Axitinib 65Ipilimumab 62aldesleukin 52Magnetic Resonance Spectroscopy 45Cyclophosphamide 40Interleukin-2 38lenvatinib 37Specimen Handling 36Radiosurgery 36Interferon-alpha 32atezolizumab 30temsirolimus 27belzutifan 24Gemcitabine 23fludarabine phosphate 22avelumab 22Radiotherapy 19Interferon alpha-2 19Biopsy 18fludarabine 17durvalumab 17Nephrectomy 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × ABT751 × Genitourinary × Clear all
NCT00073112 2007-11-29

A Study of ABT-751 in Patients With Renal Cell Cancer

Abbott

Phase 2 Completed
60 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡